Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-09 · 1879 (5) · 189155
DOI: 10.1016/j.bbcan.2024.189155 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-09. Verfasst von Gabriela E Wachholz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Angiogenesis Laboratory, Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Clonal Anergy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cell therapy presents significant results, especially for the treatment of hematologic malignancies. However, there are limitations and challenges to be overcome to achieve similar success for the treatment of solid tumors. These challenges involve selection of the target, infiltration into the tumor microenvironment and maintenance of functionality. The tumor vasculature is a major barrier for leukocytes to enter the tumor parenchyma. Due to the exposure of the vasculature to angiogenic growth factors during tumor progression, the endothelial cells become anergic to inflammatory cytokines, resulting in reduced leukocyte adhesion molecule expression. As such adhesion molecules are a prerequisite for leukocyte extravasation, endothelial cell anergy allows tumors to escape from endogenous immunity, as well as from cellular immunotherapies such as CAR T cells. Hence, overcoming endothelial cell anergy, e.g. through the administration of angiogenesis inhibitors, is believed to restore anti-tumor immunity. Concomitantly, both endogenous immune cells as well as cellular therapeutics such as CAR T cells can permeate into the tumor parenchyma. Here, we discuss how prior or concomitant treatment with an antiangiogenic drug can improve CAR T cell therapy, to become an attractive strategy for the treatment of solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Angiogenesis Laboratory, Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, the Netherlands.
- Angiogenesis Laboratory, Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, the Netherlands. Electronic address: a.griffioen@amsterdamumc.nl.
Zitieren
APA
Wachholz, G. E., Akbari, P., Huijbers, E. J. M., Jalan, P., van Beijnum, J. R., & Griffioen, A. W. (2024). Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(5), 189155. https://doi.org/10.1016/j.bbcan.2024.189155
Vancouver
Wachholz GE, Akbari P, Huijbers EJM, Jalan P, van Beijnum JR, Griffioen AW. Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(5):189155. doi:10.1016/j.bbcan.2024.189155
BibTeX
@article{Wachholz2024,
author = {Wachholz, Gabriela E and Akbari, Parvin and Huijbers, Elisabeth J M and Jalan, Prachi and van Beijnum, Judy R and Griffioen, Arjan W},
title = {Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
volume = {1879},
number = {5},
pages = {189155},
doi = {10.1016/j.bbcan.2024.189155}
}
EUVIMED